Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
Stopped early · Phase 1/Phase 2
Conditions studied: Multiple Myeloma
In brief
This is a Phase 1/2 study designed to evaluate the safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma whose disease has progressed after 3 or more prior systemic therapies.
Key facts
- Study ID
- NCT03340883
- Run by
- Chinook Therapeutics, Inc.
- People needed
- 21
- Starts
- 2017-11-15
- Expected to finish
- 2019-07-09
- Last updated by the study team
- 2021-04-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- James R. Berenson, MD, Inc — West Hollywood, California, United States
- Winship Cancer Institute/Emory University — Atlanta, Georgia, United States
- Ohio State University Wexner Medical Center James Cancer Hospital — Columbus, Ohio, United States
- UPMC (University of Pittsburgh Medical Center) Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
- Swedish Medical Center — Seattle, Washington, United States
- Froedtert Hospital & The Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.